TVTX
Travere Therapeutics, Inc.
Key Financials
Operating Income
$-62824000
↑ 80.6%
Revenue
$490.7M
↑ 110.5%
Net Income
$-25546000
↑ 92.1%
EPS (Diluted)
$-0.29
↑ 92.9%
Total Liabilities
$490.4M
↓ 8.4%
Total Assets
$605.2M
↑ 1.9%
Shareholders' Equity
$114.8M
↑ 94.4%
Cash & Equivalents
$93.0M
↑ 58.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/22/2026 | View on SEC |
| S-8 | 6/17/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 8-K | 6/16/2026 | View on SEC |
| 144 | 6/12/2026 | View on SEC |
| 144 | 6/12/2026 | View on SEC |
| 8-K | 6/2/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TVTX |
| Company Name | Travere Therapeutics, Inc. |
| CIK | 1438533 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | CA |
| Phone | 888-969-7879 |